The Technical Analyst
NovaBay Pharmaceuticals [NBY]
Exchange: AMEX Industry: Biotechnology
NovaBay Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.90% $0.0824
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.97 mill |
| EPS: | -3.96 |
| P/E: | -0.0200 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 36.06 mill |
| Avg Daily Volume: | 3.53 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0200 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0694 - 0.0954 ( +/- 15.78%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-09 | Freiman Paul E. | Buy | 858 | Restricted Stock Units |
| 2023-06-09 | Garlikov Julie | Buy | 858 | Restricted Stock Units |
| 2023-06-09 | Zheng Yenyou | Buy | 858 | Restricted Stock Units |
| 2023-06-09 | Zheng Yongxiang | Buy | 858 | Restricted Stock Units |
| 2023-06-09 | Sit Swan | Buy | 858 | Restricted Stock Units |
| INSIDER POWER |
|---|
| -47.90 |
| Last 96 transactions |
| Buy: 2 335 940 | Sell: 2 184 002 |
Forecast:
16:00 - $0.0800
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0800
Forecast 2: 16:00 - $0.0800
Forecast 3: 16:00 - $0.0800
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0824 (-1.90% ) |
| Volume | 1.606 mill |
| Avg. Vol. | 3.53 mill |
| % of Avg. Vol | 45.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NBY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NBY
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Latest Press Releases
2024-04-19 18:00:00 - Press Release
Novabay Pharmaceuticals Receives A Nyse American Notice Regarding Stockholder Equity
Emeryville, calif.--(business wire)--novabay® pharmaceuticals, inc. (nyse american: nby) announces that on april 18, 2024 it received a notice from the nyse american llc stating that the company is below compliance with the nyse american continued listing standards set forth in sections 1003(a)(ii) and (iii) of the nyse american company guide pursuant to stockholders equity. the company must submit a plan by may 18, 2024 advising of actions it has taken or will take to regain compliance with th.
2024-04-17 06:59:00 - Press Release
Novabay Pharmaceuticals Reports Preliminary Eyecare And Wound Care Revenue Increased 13% For The First Quarter Of 2024 On Lower Sales And Marketing Expenses
Emeryville, calif.--(business wire)--novabay® pharmaceuticals, inc. (nyse american: nby) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. this increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the company's lead product, avenova antimicrobial lid & lash solution. “we started.
2024-03-26 16:05:00 - Press Release
Novabay Pharmaceuticals Reports 2023 Fourth Quarter And Full Year Financial Results
Emeryville, calif.--(business wire)--novabay® pharmaceuticals, inc. (nyse american: nby) reports financial results for the three and 12 months ended december 31, 2023 and provides a business update. “quarterly revenue from our eyecare and wound care segment increased 10% versus the prior year, driven by higher avenova sales through our physician dispensed and otc channels, and by higher sales of our branded wound care products,” said justin hall, ceo of novabay. “last year we expanded our loyal.
2024-03-25 18:38:00 - Press Release
Novabay Pharmaceuticals To Hold 2023 Fourth Quarter And Full Year Conference Call On March 26, 2024
Emeryville, calif.--(business wire)--novabay® pharmaceuticals, inc. (nyse american: nby) announces that it will report financial results for the three and 12 months ended december 31, 2023 after market close on tuesday, march 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. eastern time. date/time: tuesday, march 26, 4:30 p.m. et / 1:30 p.m. pt pre-registration: participants can pre-register for the conference call here: callers.
2024-03-14 08:00:00 - Press Release
Novabay Pharmaceuticals Announces Agreement To Sell Its Dermadoctor Skincare Business Segment; Announces Preliminary Financial Results For Fourth Quarter And Year Ended December 31, 2023
Emeryville, calif.--(business wire)--novabay® pharmaceuticals, inc. (nyse american: nby), a company developing and commercializing high-quality eyecare and wound care products, announces that the company has entered into an agreement to sell its dermadoctor® skincare business including all product inventory for approximately $1.0 million in cash. novabay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. “.
Latest News
2024-03-25 18:38:00 - Business Wire
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers.
2023-11-09 23:43:05 - Seeking Alpha
NovaBay Pharmaceuticals, Inc. (NBY) Q3 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - CEO and General Counsel Tommy Law - Interim CFO Conference Call Participants Destiny Buch - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-11-02 06:50:00 - Business Wire
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, November 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers w.
2023-10-02 06:50:00 - Business Wire
NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Harborside Hotel in Jupiter, Fla. “We are excited to showcase the innovative produc.
2023-08-12 14:40:24 - Seeking Alpha
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-05-24 06:50:00 - Business Wire
NovaBay Pharmaceuticals to Present at the Emerging Growth Virtual Conference on May 31, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, Chief Executive Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, May 31, 2023 at 1:10 p.m. Eastern time (10:10 a.m. Pacific time). To attend the NovaBay presentation, submit questions in advance of the presentation and receive updates,.
2023-05-22 06:35:00 - PennyStocks
Looking for Undervalued Penny Stocks? Use These Tips
Understanding the stock market can be a challenging endeavor, yet it offers vast potential for substantial gains, particularly when it comes to penny stocks. Penny stocks, which typically trade below $5 per share, offer an accessible route to market participation, often piquing the interest of investors seeking higher returns with lower capital.
2023-05-21 06:00:00 - PennyStocks
Penny Stock Investing, 3 High-Growth Industries to Watch
Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-05-04 06:50:00 - Business Wire
NovaBay Pharmaceuticals to Hold First Quarter 2023 Conference Call on May 11, 2023
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, May 11, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-regi.
2023-04-21 10:22:56 - PennyStocks
Penny Stocks To Buy Now? 5 With Big News Today
Penny stocks news sparks momentum in the stock market today. The post Penny Stocks To Buy Now?